-
1
-
-
0026593561
-
Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia
-
Gucalp R., Ritch P., Wiernik P., et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 10 (1992) 134
-
(1992)
J Clin Oncol
, vol.10
, pp. 134
-
-
Gucalp, R.1
Ritch, P.2
Wiernik, P.3
-
2
-
-
0023877970
-
Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonates AHPrBP
-
Thiebaud D., Jaeger P.H., Jacquet A.F., et al. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonates AHPrBP. J Clin Oncol 6 (1988) 762
-
(1988)
J Clin Oncol
, vol.6
, pp. 762
-
-
Thiebaud, D.1
Jaeger, P.H.2
Jacquet, A.F.3
-
3
-
-
0035863508
-
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials
-
Major P., Lartholory A., Joh J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19 (2001) 558
-
(2001)
J Clin Oncol
, vol.19
, pp. 558
-
-
Major, P.1
Lartholory, A.2
Joh, J.3
-
4
-
-
0346363760
-
The role of the Wnt/β-catenin signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
-
Tian E., Ahan F., Walker R., et al. The role of the Wnt/β-catenin signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 (2003) 2483
-
(2003)
N Engl J Med
, vol.349
, pp. 2483
-
-
Tian, E.1
Ahan, F.2
Walker, R.3
-
5
-
-
9044219839
-
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
-
Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334 (1996) 488
-
(1996)
N Engl J Med
, vol.334
, pp. 488
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
-
6
-
-
6844252283
-
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
-
Berenson J.R., Lichtenstein A., Porter L., et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16 (1998) 593
-
(1998)
J Clin Oncol
, vol.16
, pp. 593
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
-
7
-
-
10744233021
-
Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma
-
Rosen L.S., Gordon D., Kaminski M., et al. Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Am Cancer Soc 98 (2003) 1735
-
(2003)
Am Cancer Soc
, vol.98
, pp. 1735
-
-
Rosen, L.S.1
Gordon, D.2
Kaminski, M.3
-
8
-
-
0036729485
-
American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
-
Berenson J.R., Hillner B.E., Kyle R.A., et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719
-
(2002)
J Clin Oncol
, vol.20
, pp. 3719
-
-
Berenson, J.R.1
Hillner, B.E.2
Kyle, R.A.3
-
9
-
-
34347260332
-
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
-
Kyle R.A., Yee G.C., Sommerfield M.R., et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25 (2007) 2464
-
(2007)
J Clin Oncol
, vol.25
, pp. 2464
-
-
Kyle, R.A.1
Yee, G.C.2
Sommerfield, M.R.3
-
10
-
-
33746855407
-
Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma
-
Lacy M.Q., Dispenzeri A., Giertz M.A., et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81 (2006) 1047
-
(2006)
Mayo Clin Proc
, vol.81
, pp. 1047
-
-
Lacy, M.Q.1
Dispenzeri, A.2
Giertz, M.A.3
-
11
-
-
0035425227
-
Biology of osteoclast activation in cancer
-
Roodman G.D. Biology of osteoclast activation in cancer. J Clin Oncol 19 (2008) 3562
-
(2008)
J Clin Oncol
, vol.19
, pp. 3562
-
-
Roodman, G.D.1
-
12
-
-
0027531814
-
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
-
Paterson A.H.G., Powles T.J., Kanis J.A., et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11 (1993) 59
-
(1993)
J Clin Oncol
, vol.11
, pp. 59
-
-
Paterson, A.H.G.1
Powles, T.J.2
Kanis, J.A.3
-
13
-
-
10544228130
-
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
-
Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 24 (2005) 1785
-
(2005)
N Engl J Med
, vol.24
, pp. 1785
-
-
Hortobagyi, G.N.1
Theriault, R.L.2
Porter, L.3
-
14
-
-
0029782630
-
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial
-
Conte P.F., Latreille L., Mauriac F., et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. J Clin Oncol 14 (2008) 2552
-
(2008)
J Clin Oncol
, vol.14
, pp. 2552
-
-
Conte, P.F.1
Latreille, L.2
Mauriac, F.3
-
15
-
-
0033050818
-
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
-
Theriault R.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. J Clin Oncol 17 (1999) 846
-
(1999)
J Clin Oncol
, vol.17
, pp. 846
-
-
Theriault, R.L.1
Lipton, A.2
Hortobagyi, G.N.3
-
16
-
-
0034062815
-
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
-
Hillner B.E., Ingle J.N., Berenson J.R., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18 (2000) 1378
-
(2000)
J Clin Oncol
, vol.18
, pp. 1378
-
-
Hillner, B.E.1
Ingle, J.N.2
Berenson, J.R.3
-
17
-
-
0642342669
-
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
-
Hillner B.E., Ingle J.N., Chelbowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042
-
(2003)
J Clin Oncol
, vol.21
, pp. 4042
-
-
Hillner, B.E.1
Ingle, J.N.2
Chelbowski, R.T.3
-
18
-
-
35348897212
-
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases
-
Lipton A., Steger G.T.G., Figueroa J., et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 28 (2007) 4431
-
(2007)
J Clin Oncol
, vol.28
, pp. 4431
-
-
Lipton, A.1
Steger, G.T.G.2
Figueroa, J.3
-
19
-
-
56749102816
-
Cancer treatment-induced bone loss in breast and prostate cancer
-
Saad F., Adachi J.D., Brown J.P., et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 33 (2008) 5465
-
(2008)
J Clin Oncol
, vol.33
, pp. 5465
-
-
Saad, F.1
Adachi, J.D.2
Brown, J.P.3
-
20
-
-
41949094767
-
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
-
Eastell R., Adams J.E., Coleman R.E., et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26 (2008) 1051
-
(2008)
J Clin Oncol
, vol.26
, pp. 1051
-
-
Eastell, R.1
Adams, J.E.2
Coleman, R.E.3
-
21
-
-
33846545851
-
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomized controlled trial
-
Coombes R.C., Kilbuirn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomized controlled trial. Lancet 570 (2007) 559
-
(2007)
Lancet
, vol.570
, pp. 559
-
-
Coombes, R.C.1
Kilbuirn, L.S.2
Snowdon, C.F.3
-
22
-
-
24744450378
-
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA 17
-
Gross P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA 17. J Natl Cancer Inst 97 (2006) 1262
-
(2006)
J Natl Cancer Inst
, vol.97
, pp. 1262
-
-
Gross, P.E.1
Ingle, J.N.2
Martino, S.3
-
23
-
-
33947510501
-
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update study BIG 1-98
-
Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update study BIG 1-98. J Clin Oncol 25 (2007) 486
-
(2007)
J Clin Oncol
, vol.25
, pp. 486
-
-
Coates, A.S.1
Keshaviah, A.2
Thurlimann, B.3
-
24
-
-
0035879298
-
Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer
-
Shapiro C.L., Manola J., and Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19 (2001) 3306
-
(2001)
J Clin Oncol
, vol.19
, pp. 3306
-
-
Shapiro, C.L.1
Manola, J.2
Leboff, M.3
-
25
-
-
0031057249
-
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study
-
Delmas P.D., Balena R., Confravreux E., et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15 (1997) 955
-
(1997)
J Clin Oncol
, vol.15
, pp. 955
-
-
Delmas, P.D.1
Balena, R.2
Confravreux, E.3
-
26
-
-
54249151531
-
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer
-
Hershman D.L., McMahon D.J., Crew K.D., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26 (2008) 4739
-
(2008)
J Clin Oncol
, vol.26
, pp. 4739
-
-
Hershman, D.L.1
McMahon, D.J.2
Crew, K.D.3
-
27
-
-
33947539707
-
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
-
Gnant M.F.X., Mlineritsch B., Luschin-Ebengreuth G., et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25 (2008) 820
-
(2008)
J Clin Oncol
, vol.25
, pp. 820
-
-
Gnant, M.F.X.1
Mlineritsch, B.2
Luschin-Ebengreuth, G.3
-
28
-
-
52049093463
-
Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early stage breast cancer
-
Saarto T., Vehmanen L., Blonqvist C., et al. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early stage breast cancer. J Clin Oncol 26 (2008) 4289
-
(2008)
J Clin Oncol
, vol.26
, pp. 4289
-
-
Saarto, T.1
Vehmanen, L.2
Blonqvist, C.3
-
29
-
-
58149166777
-
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer
-
Lester J.E., Dodwell D., Omprakash P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14 (2008) 6336
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6336
-
-
Lester, J.E.1
Dodwell, D.2
Omprakash, P.3
-
30
-
-
45749127094
-
Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blind, placebo-controlled clinical trial
-
Greenspan S.L., Brofsky A., Lembersky B.C., et al. Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26 (2008) 2644
-
(2008)
J Clin Oncol
, vol.26
, pp. 2644
-
-
Greenspan, S.L.1
Brofsky, A.2
Lembersky, B.C.3
-
31
-
-
33947524592
-
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
-
Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25 (2007) 829
-
(2007)
J Clin Oncol
, vol.25
, pp. 829
-
-
Brufsky, A.1
Harker, W.G.2
Beck, J.T.3
-
32
-
-
39749155815
-
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole ZO-FAST study results
-
Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole ZO-FAST study results. Cancer 112 (2008) 1001
-
(2008)
Cancer
, vol.112
, pp. 1001
-
-
Bundred, N.J.1
Campbell, I.D.2
Davidson, N.3
-
33
-
-
45749089797
-
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole
-
Brufsky A., Bundred N., Coleman R., et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13 (2008) 503
-
(2008)
Oncologist
, vol.13
, pp. 503
-
-
Brufsky, A.1
Bundred, N.2
Coleman, R.3
-
34
-
-
54449084015
-
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer
-
Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26 (2008) 4875
-
(2008)
J Clin Oncol
, vol.26
, pp. 4875
-
-
Ellis, G.K.1
Bone, H.G.2
Chlebowski, R.3
-
35
-
-
56749165071
-
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-A long-term follow-up
-
Diel J., Jaschke A., Solomayer E.F., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-A long-term follow-up. Ann Oncol 19 (2008) 2007
-
(2008)
Ann Oncol
, vol.19
, pp. 2007
-
-
Diel, J.1
Jaschke, A.2
Solomayer, E.F.3
-
36
-
-
0036682211
-
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer
-
Powles T., Paterson S., Kanis J.A., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20 (2002) 3219
-
(2002)
J Clin Oncol
, vol.20
, pp. 3219
-
-
Powles, T.1
Paterson, S.2
Kanis, J.A.3
-
37
-
-
0035148170
-
Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomized controlled trial
-
Saarto T., Blomqvist C., Virkkunen P., et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomized controlled trial. J Clin Oncol 19 (2001) 10
-
(2001)
J Clin Oncol
, vol.19
, pp. 10
-
-
Saarto, T.1
Blomqvist, C.2
Virkkunen, P.3
-
38
-
-
60549097419
-
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
-
Gnant M., Mlineritsch B., and Schippinger W. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Eng J Med 360 (2009) 679
-
(2009)
New Eng J Med
, vol.360
, pp. 679
-
-
Gnant, M.1
Mlineritsch, B.2
Schippinger, W.3
-
39
-
-
0042914647
-
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial
-
Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
-
Rosen L.S., Gordon D., Tchekmedyian, et al., Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial. J Clin Oncol 21 (2008) 3150
-
(2008)
J Clin Oncol
, vol.21
, pp. 3150
-
-
Rosen, L.S.1
Gordon, D.2
Tchekmedyian3
-
40
-
-
0642337996
-
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium of the palliation of bone pain in men with metastatic prostate cancer
-
Small E.J., Smith M.R., Seaman J.J., et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium of the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21 (2003) 4277
-
(2003)
J Clin Oncol
, vol.21
, pp. 4277
-
-
Small, E.J.1
Smith, M.R.2
Seaman, J.J.3
-
41
-
-
0037009822
-
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
-
Saad F., Gleson D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1458
-
-
Saad, F.1
Gleson, D.M.2
Murray, R.3
-
42
-
-
11844252588
-
Risk of fracture after androgen deprivation for prostate cancer
-
Shahinian R.B., Yong-Fang K., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 64 (2005) 154
-
(2005)
N Engl J Med
, vol.64
, pp. 154
-
-
Shahinian, R.B.1
Yong-Fang, K.2
Freeman, J.L.3
-
43
-
-
0035960116
-
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer
-
Smith M.R., McGovern F.J., Zeitman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948
-
(2001)
N Engl J Med
, vol.345
, pp. 948
-
-
Smith, M.R.1
McGovern, F.J.2
Zeitman, A.L.3
-
44
-
-
0035960116
-
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer
-
Smith M.R., McGovern F.J., Zeitman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948
-
(2001)
N Engl J Med
, vol.345
, pp. 948
-
-
Smith, M.R.1
McGovern, F.J.2
Zeitman, A.L.3
|